POLYMORPHISMS AS PREDICTORS OF TREATMENT RESPONSE AND OVERALL SURVIVAL OF METASTATIC COLORECTAL CANCER

摘要

The present disclosure relates to methods for determining whether a subject with cancer, in particular metastatic colorectal cancer, is likely to respond to treatment and/or predicting overall survival with bevacizumab and fluoropyrimidine-based chemotherapy. The present disclosure also relates to methods of selecting a treatment of a subject's cancer and compounds for use in the treatment of the subject's cancer. The present disclosure also relates to kits that can be utilised in these methods.